Bios Capital Management
$42M 13F equity value
6 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Bios Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ACTU | ACTUATE THERAPEUTICS INC | 10,049,996 | $15M | 36.9% |
| IRD | OPUS GENETICS INC | 3,683,429 | $15M | 36.3% |
| CGTX | COGNITION THERAPEUTICS INC | 6,000,000 | $7M | 16.6% |
| RNTX | REIN THERAPEUTICS INC | 2,982,375 | $3M | 7.4% |
| LTRN | LANTERN PHARMA INC | 249,397 | $1M | 2.5% |
| INAB | IN8BIO INC | 80,957 | $114,149 | 0.3% |
Track Bios Capital Management's 13F portfolio: $42M in reported holdings, 6 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}